- AU$6.98m
- AU$8.23m
- AU$4.53m
Australia Stock Exchange release from ACRUX : PRE_NR Ends: 08:42:46
Australia Stock Exchange release from ACRUX : Acrux and Harris terminate license agreement
Australia Stock Exchange release from ACRUX : Annual General meeting and date for director nominations
Australia Stock Exchange release from ACRUX : Appendix 3Y - Ross Dobinson
Australia Stock Exchange release from ACRUX : Application for quotation of securities - ACR
Australia's Acrux rises as U.S. FDA plans to review its acne treatment gel
Brief: Acrux Says Us FDA Accepted For Review Co's Abbreviated New Drug Application
Australia Stock Exchange release from ACRUX : PRE_NR Ends: 08:33:19
Australia Stock Exchange release from ACRUX : Acrux's fifth generic dossier accepted by FDA for review
Australia Stock Exchange release from ACRUX : Acrux Investor Presentation - September 2021
Australia Stock Exchange release from ACRUX : PRE_NR Ends: 08:40:29
Australia Stock Exchange release from ACRUX : US Launch - Testosterone Topical Solution
Australia Stock Exchange release from ACRUX : PRE_NR Ends: 09:45:55
Brief: Acrux Says FY Loss After Tax A$ 12.63 Mln Versus A$ 9.471 Mln Loss Year Ago
Australia Stock Exchange release from ACRUX : Appendix 4G and Corporate Governance Statement
Australia Stock Exchange release from ACRUX : Appendix 4E and Financial Report
Australia Stock Exchange release from ACRUX : PRE_NR Ends: 13:51:39
Brief: Acrux Gets U.S. FDA Approval For Generic Version Of EMLA Cream
Australia Stock Exchange release from ACRUX : Notification of cessation of securities - ACR